

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the captioned application:

Listing of Claims:

Claim 1 (currently amended): A swallowable immediate release tablet ~~comprising~~ consisting essentially of at least 60 weight % of acetaminophen, ~~and~~ from about 1 to about 10 weight % of a powdered wax having an melting point greater than about 90° C and a particle size in the range of about 5 to about 100 microns, and less than about 25 weight % of a disintegrant, wherein the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 2 (cancelled)

Claim 3 (previously presented): The tablet of claim 1, wherein the wax is selected from the group consisting of linear hydrocarbons, microcrystalline wax, and mixtures thereof.

Claim 4 (previously presented): The tablet of claim 1 prepared by direct compression.

Claim 5 (previously presented): The tablet of claim 1 which is substantially free of water-soluble, non-saccharide polymeric binders.

Claim 6 (previously presented): The tablet of claim 1, which is substantially free of hydrated polymers.

Claim 7 (previously presented): The tablet of claim 1 further comprising at least one outer coating.

Claim 8 (previously presented): The tablet of claim 7, wherein the outer coating comprises a material selected from the group consisting of gelatin, isomalt, monosaccharides, disaccharides, polysaccharides such as starch, cellulose derivatives, shellacs, polyhedric alcohols such as xylitol, mannitol, sorbitol, maltitol, erythritol, and polyalkylene glycols.

Claim 9 (cancelled)

Claim 10 (currently amended): The tablet of claim 1 further comprising an excipient selected from the group consisting of ~~disintegrants~~, flow aids, and ~~optionally~~ lubricants.

Claim 11 (previously presented): The tablet of claim 1 further comprising an insert disposed within tablet.

Claim 12 (previously presented): The tablet of claim 11, wherein the insert comprises additional active ingredient.

Claim 13 (previously presented): The tablet of claim 12, wherein the additional active ingredient has a different release profile from the active ingredient in the tablet.

Claim 14 (previously presented): The tablet of claim 12, wherein the amount of additional active ingredient is from about 0.1 to about 30 mg.

Claim 15 (previously presented): The tablet of claim 12, wherein the additional active ingredient is selected from the group consisting of loratadine, fexofenadine, cetirizine, chlorpheniramine, brompheniramine, diphenhydramine, pseudoephedrine, cyproheptadine, montelukast, loperamide, famotidine, dexamethasone, hydrocortisone, cyclobenzaprine, alendronate, hydrochlorthiazide, rofecoxib, indomethacin, ketoprofen, meloxicam, piroxicam, lovastatin, atorvastatin, pravastatin, simvastatin, finasteride, and pharmaceutically acceptable salts, esters, and mixtures thereof.

Claim 16 (cancelled)

Claim 17 (currently amended): A swallowable immediate release tablet ~~comprising~~ consisting essentially of at least 60 weight percent of acetaminophen, ~~and~~ from about 1 to about 10 weight % of a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof, and less than about 25 weight % of a disintegrant, wherein said swallowable immediate release tablet is prepared by direct compression, and the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 18 (currently amended): A swallowable immediate release tablet ~~comprising~~ consisting essentially of at least 60 weight percent of acetaminophen, ~~and~~ from about 1 to about 10 weight % of a powdered wax having a particle size in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof, and less than about 25 weight % of a disintegrant, wherein said swallowable immediate release tablet is substantially free of water-soluble, non-saccharide polymeric binders, and the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 19 (currently amended): A swallowable immediate release tablet ~~comprising~~ consisting essentially of at least 60 weight percent of acetaminophen, ~~and~~ from about 1 to about 10 weight % of a powdered wax having a particle size in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof, and less than about 25 weight % of a disintegrant, wherein said swallowable immediate release tablet is substantially free of hydrated polymers, and the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 20 (cancelled):